| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05035680 Details | 2022-11-17 Interventional | 1 | 0 | Vaccines Influenza, Huma… Influenza | Study cancelled - | |||
| NCT04311515 Details | 2022-11-17 Interventional | 2 | 4 | Fluorodeoxygluc… Alzheimer Disea… Dementia | Samus Therapeutics company closure - | |||
| NCT03935555 Details | 2022-11-17 Interventional | 1 | 11 | 9H-purine-9-pro… Polycythemia Polycythemia Ve… Primary Myelofi… Thrombocythemia… Thrombocytosis Post-Essential … Post-Polycythem… Primary Myelofi… | Samus Therapeutics company closure - | |||
| NCT02783547 Details | 2022-11-17 Interventional | 1 | 0 | Azacitidine Myelodysplastic… Preleukemia Syndrome Myelodysplastic… | The trial was withdrawn due to problems with the manufacture of the investigational drug. - | |||
| NCT03632642 Details | 2022-11-16 Interventional | 4 | 0 | Floxacillin Penicillin G Penicillin G Be… Penicillin G Pr… Staphylococcal … Staphylococcus … | Study never commenced - | |||
| NCT03515629 2017-001041-27 Details | 2022-11-16 Interventional | 3 | 5 | Cemiplimab Pembrolizumab Carcinoma, Non-… Lung Neoplasms Non-small Cell … | Business decision - | |||
| NCT02947581 Details | 2022-11-16 Interventional | 3 | 107 | Albendazole Praziquantel Cysticercosis Neurocysticerco… Taeniasis | Albendazole and albendazole placebo are not available in our local suppliers or in the
international market. Consequently, it is no possible to re-initiate the enrollment to complete
the original sample size. - | |||
| NCT05438758 Details | 2022-11-15 Interventional | 2 | 0 | Esketamine Ketamine Depression Depressive Diso… Depressive Diso… Treatment Resis… | Withdrawn by Sponsor - | |||
| NCT05093387 Details | 2022-11-15 Interventional | 1 | 0 | Carboplatin Pembrolizumab Breast Neoplasm… Carcinoma Inflammatory Br… Anatomic Stage … Breast Inflamma… Metastatic Trip… Prognostic Stag… | funding issues and pharmacy preparation for the drug - | |||
| NCT03373877 Details | 2022-11-15 Interventional | 1 | 4 | 9H-purine-9-pro… Polycythemia Polycythemia Ve… Primary Myelofi… Thrombocythemia… Thrombocytosis Myelofibrosis Post-essential … Post-polycythem… | Samus is focusing all of their efforts in myelofibrosis on the new oral formulation of PU-H71. - | |||
| NCT01905592 Details | 2022-11-15 Interventional | 3 | 216 | Niraparib Breast Neoplasm… Carcinoma Neoplasms Ovarian Neoplas… BRCA1 Gene Muta… BRCA2 Gene Muta… Carcinoma of Br… Human Epidermal… Neoplasms, Brea… | The study was terminated due to futility. IDMC interim analysis concluded that concerns with the quantity and quality of data in the control arm precluded meaningful comparative analyses and generation of a clinically useful endpoint, therefore enrollment was ended prematurely. | |||
| NCT00945269 Details | 2022-11-15 Interventional | 1/2 | 3 | Aldesleukin Denileukin dift… Immunotoxins Interleukin-2 Melanoma Recurrent Melan… Stage III Melan… Stage IV Melano… | ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer be
supporting clinical trials that utilize this drug. - | |||
| NCT05309902 Details | 2022-11-14 Interventional | 1 | 0 | Moxifloxacin Healthy Volunte… | Study not needed - | |||
| NCT02263508 2014-000185-22 Details | 2022-11-14 Interventional | 3 | 713 | Pembrolizumab Talimogene lahe… Melanoma | - - | |||
| NCT01881789 Details | 2022-11-14 Interventional | 1/2 | 22 | Cyclophosphamid… Dexamethasone Lenalidomide Multiple Myelom… Neoplasms, Plas… | A program evaluation identified that the safety profile and pharmacokinetic (PK)
characteristics of the formulation used in all oprozomib studies required further optimization
and thus enrollment in OPZ003 was halted during dose-escalation. - | |||
| NCT04687800 Details | 2022-11-10 Interventional | 4 | 1 | Dexamethasone Difluprednate Cataract | Inability to enroll due to lack of access to the Ambulatory Surgery Center. - | |||
| NCT03784599 Details | 2022-11-10 Interventional | 2 | 28 | Ado-Trastuzumab… Maytansine Osimertinib Trastuzumab Carcinoma, Non-… | insufficient effectiveness - | |||
| NCT05611086 Details | 2022-11-09 Interventional | 4 | 16 | Acetylcysteine N-monoacetylcys… Leukemia Precursor Cell … Lymphoblastic L… | The study stopped because the study period already ended - | |||
| NCT04940871 Details | 2022-11-09 Interventional | 2 | 1 | Favipiravir Severe Acute Re… Severe Acute Re… | Only one patient was enrolled, who who later withdrew the consent. They decided not to contunie
the study. - | |||
| NCT04375202 2020-001475-33 Details | 2022-11-07 Interventional | 2 | 227 | Colchicine COVID-19 | Insufficient rate of patient accrual and newly available scientific evidence - |